Anastasiya Sybirna
Board Observer
![](https://t-therapeutics.com/wp-content/uploads/2023/10/t-cell-bind-300x61.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Anastasia_Sybirna.jpg)
Anastasiya is a healthcare investor with F-Prime Capital based in London. She is a Board Observer for T-Therapeutics, as well as two other F-Prime portfolio companies in the fields of intrinsically disordered proteins and cellular rejuvenation.
Prior to joining F-Prime, Ana was an Engagement Manager at McKinsey specialising in Pharmaceuticals & Medical Products and had previously worked as a Strategy Consultant at Advancy.
Ana holds a Ph.D. in Stem Cell Biology and Medicine from the University of Cambridge (UK), a MSc in Molecular and Cell Biology from École normale supérieure (Paris, France) and a BSc in Biology from Ivan Franko National University of Lviv (Ukraine).
![](https://t-therapeutics.com/wp-content/uploads/2023/10/T-Therapeutics_icon-footer-150x150.png)